Raymond James & Associates raised its holdings in shares of Ishares Nasdaq Biotechnology (NASDAQ:IBB) by 231.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 278,618 shares of the financial services provider’s stock after buying an additional 194,513 shares during the quarter. Raymond James & Associates owned about 0.32% of Ishares Nasdaq Biotechnology worth $29,750,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently modified their holdings of the business. Parametric Portfolio Associates LLC grew its holdings in shares of Ishares Nasdaq Biotechnology by 8.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 988 shares of the financial services provider’s stock worth $306,000 after acquiring an additional 79 shares during the period. Orleans Capital Management Corp LA lifted its position in Ishares Nasdaq Biotechnology by 13.4% in the 3rd quarter. Orleans Capital Management Corp LA now owns 1,695 shares of the financial services provider’s stock valued at $565,000 after acquiring an additional 200 shares in the last quarter. Apriem Advisors lifted its position in Ishares Nasdaq Biotechnology by 19.3% in the 3rd quarter. Apriem Advisors now owns 1,360 shares of the financial services provider’s stock valued at $454,000 after acquiring an additional 220 shares in the last quarter. Allianz Asset Management GmbH lifted its position in Ishares Nasdaq Biotechnology by 20.0% in the 3rd quarter. Allianz Asset Management GmbH now owns 1,800 shares of the financial services provider’s stock valued at $601,000 after acquiring an additional 300 shares in the last quarter. Finally, FNY Partners Fund LP bought a new position in Ishares Nasdaq Biotechnology in the 3rd quarter valued at approximately $133,000. 62.05% of the stock is owned by hedge funds and other institutional investors.
Ishares Nasdaq Biotechnology stock traded down $3.14 during trading on Friday, reaching $101.03. The company had a trading volume of 2,840,400 shares, compared to its average volume of 2,502,108. Ishares Nasdaq Biotechnology has a 52 week low of $94.20 and a 52 week high of $119.30.
COPYRIGHT VIOLATION NOTICE: “Ishares Nasdaq Biotechnology (IBB) Shares Bought by Raymond James & Associates” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/raymond-james-associates-grows-holdings-in-ishares-nasdaq-biotechnology-index-ibb.html.
Ishares Nasdaq Biotechnology Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Receive News & Ratings for Ishares Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ishares Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.